Top Story Today
The "Undruggable" Target Just Got Drugged: A Pill Rewrites Pancreatic Cancer's Odds
Revolution Medicines' Phase 3 pancreatic cancer trial completed its first interim analysis and met all primary endpoints. Patients taking daraxonrasib, a once-daily pill, lived a median of 13.2 months compared to 6.7 months on chemo: a 60% reduction in death risk. The drug targets RAS, a protein family driving over 90% of pancreatic cancers that scientists spent 40 years failing to crack. The stock surged 35%, and analysts across Wall Street hiked price targets. Even former U.S. Senator Ben Sasse enrolled in an early trial, calling it his "best, only option."
Why it matters: Pancreatic cancer has been oncology's most immovable wall, with 3% five-year survival in metastatic patients. These results validate the RAS-targeting approach and could reshape treatment for a disease where progress has historically been measured in weeks, not months.
Read more →Obesity Wars and Regulatory Moves
Lilly's New Obesity Pill Got Record-Fast Approval. The FDA Still Wants Liver Receipts.
Foundayo (orforglipron) became the second oral GLP-1 obesity pill on the market, earning FDA approval just 50 days after filing. But the agency also mandated five years of liver safety monitoring. It's precautionary, not alarming; analysts shrugged. The real story: Lilly now has a no-needle, no-fridge obesity pill priced between $149 and $349 a month.
Read more →Popular Peptides Just Got Bounced From the FDA's Approved List
An FDA advisory committee blocked peptides including ipamorelin and CJC-1295 from the compounding pharmacy playbook, citing safety risks and thin data. It's part of a broader crackdown: over 50 warning letters sent to compounded GLP-1 sellers, border seizures of Chinese peptide imports, and hard deadlines for semaglutide compounders. The $50 billion peptide market is getting a serious regulatory haircut.
Read more →Pharma's AI Arms Race
Novo Nordisk Hands OpenAI the Keys to Its Entire Drug Operation
Novo Nordisk and OpenAI announced a deal to embed AI across drug discovery, manufacturing, supply chain, and commercial operations, with full integration by year's end. This isn't a pilot project; it's a company-wide overhaul. Novo's stock popped 3.6%. With CagriSema underperforming and Lilly's pipeline pulling ahead, Novo needs the speed advantage AI promises more than ever.
Read more →A Big Pharma CEO Just Joined the Board of a Frontier AI Company. That's Never Happened.
Novartis CEO Vas Narasimhan landed a board seat at Anthropic, the AI safety company behind Claude. He's the first sitting pharma chief to govern a frontier AI firm. Anthropic gets someone who navigates the FDA for a living; Narasimhan gets a front-row seat to the tech reshaping drug discovery. With Anthropic valued at $380 billion and eyeing an IPO, healthcare is clearly a core growth bet.
Read more →Deals, Funding, and the Money Game
Bain Capital Just Built a $300M Biotech From Bristol Myers Squibb's Castoffs
Beeline Medicines launched with $300 million in Series A funding and five immunology drugs BMS decided didn't fit its strategy anymore. The CEO, Saqib Islam, previously turned a Pfizer spinout (also Bain-backed) into a $3.9 billion Merck acquisition. Same playbook, same backers, new target: lupus and autoimmune diseases that have frustrated pharma for decades.
Read more →Biotech's Youngest Companies Are Running Out of Oxygen
US biotech seed and Series A funding rounds fell 25.2% in Q1 2026, putting first-time financings on pace for their worst year since before the pandemic. Meanwhile, IPOs raised $1.7 billion at record median deal sizes. The gap is brutal: public investors want Phase 2 data, but early-stage companies need funding to generate that data in the first place. Multiple startups shut down in 2025.
Read more →Spain Just Dropped $200M to Build a Biotech Bridge to Boston
Spain announced a $200 million government-backed biotech VC fund anchored in Boston, the first time a European country has seeded a venture fund on U.S. soil. With a growing biotech sector but small average deal sizes, Spain has the science but not the capital pipeline. The fund could significantly boost the country's annual biotech funding capacity in a single vehicle.
Read more →Gene Therapy's Business Problem
This Gene Therapy Company Thinks the Industry Is Solving the Wrong Problem
Ocugen's CEO argues gene therapy's real bottleneck isn't science; it's manufacturing, pricing, and delivery. The company's lead candidate, OCU400, treats retinitis pigmentosa across 100+ mutations with a single product (instead of one custom therapy per mutation). Their Phase 3 trial just finished enrolling 140 patients, with topline data expected in early 2027. Oppenheimer initiated coverage at a $10 target versus a $1.80 stock price.
Read more →